Literature DB >> 30410209

Second steps in managing type 2 diabetes.

Carolyn J Petersons1.   

Abstract

Entities:  

Keywords:  incretin mimetics; metformin; oral hypoglycaemic drugs; sodium-glucose co-transporter 2 inhibitors; sulfonylureas; type 2 diabetes

Year:  2018        PMID： 30410209      PMCID： PMC6202300          DOI： 10.18773/austprescr.2018.043

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  9 in total

1.  Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.

Authors:  D R Matthews; S Dejager; B Ahren; V Fonseca; E Ferrannini; A Couturier; J E Foley; B Zinman
Journal:  Diabetes Obes Metab       Date:  2010-09       Impact factor: 6.577

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

3.  Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.

Authors:  B Göke; B Gallwitz; J Eriksson; A Hellqvist; I Gause-Nilsson
Journal:  Int J Clin Pract       Date:  2010-09-16       Impact factor: 2.503

4.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Authors:  Bernard Charbonnel; Avraham Karasik; Ji Liu; Mei Wu; Gary Meininger
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

5.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

Authors:  M A Nauck; G Meininger; D Sheng; L Terranella; P P Stein
Journal:  Diabetes Obes Metab       Date:  2007-03       Impact factor: 6.577

6.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

Authors:  Ralph A DeFronzo; Robert E Ratner; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

Review 7.  Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.

Authors:  Matthew P Gilbert; Richard E Pratley
Journal:  Eur J Intern Med       Date:  2009-06-21       Impact factor: 4.487

Review 8.  Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.

Authors:  J A Hirst; A J Farmer; A Dyar; T W C Lung; R J Stevens
Journal:  Diabetologia       Date:  2013-03-15       Impact factor: 10.122

9.  Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis.

Authors:  Elizabeth S Mearns; Diana M Sobieraj; C Michael White; Whitney J Saulsberry; Christine G Kohn; Yunes Doleh; Eric Zaccaro; Craig I Coleman
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240
  9 in total
  1 in total

Review 1.  Dulaglutide for type 2 diabetes.

Authors: 
Journal:  Aust Prescr       Date:  2018-09-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.